← Tilray overview

Tilray vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tilray Inc (TLRY)

Q3 2026
▲2▼1

Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble

  • BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.

    A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.

  • Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.

    This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.

  • Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.

    Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.

  • Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.

    This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.

August 2026
▲2▼1

Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble

  • BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.

    A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.

  • Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.

    This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.

  • Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.

    Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.

  • Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.

    This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.

Latest
▲2▼1

Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble

  • BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.

    A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.

  • Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.

    This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.

  • Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.

    Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.

  • Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.

    This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.